ClinicalTrials.gg
CompletedNCT00853099Updated Sep 5, 2014Results posted

A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

A Phase 3 interventional study of adalimumab and placebo in Ulcerative Colitis, sponsored by AbbVie (prior sponsor, Abbott). Completed at 65 sites in Japan. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2014-09-05.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
274
Allocation
Randomized
Ages
15 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 18 studies testing adalimumab in Colitis, Ulcerative — 1 open to participants now, 2 under way, none of them phase 3. Adalimumab · Colitis, Ulcerative.

Enrollment
6th of 18
274 · median 152
Started
2009
the only one that year
Phase 3
10 of 18
none open now
Registered
5th of 18
by date
Lead sponsor
3 of 18
AbbVie (prior sponsor, Abbott)

Among the 18 studies testing adalimumab in Colitis, Ulcerative, this one is the 6th largest by enrollment, is the only one that started in 2009, is one of 10 in phase 3, and was the 5th registered.

Colitis, Ulcerative

1,856 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

1 of the 18 studies testing adalimumab in Colitis, Ulcerative is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 306 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 135 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 15 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing adalimumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of adalimumab in Japanese subjects with moderately to severely active ulcerative colitis (UC).

Read the detailed description

Patients who meet all of the inclusion criteria and none of the exclusion criteria are randomized 1:1:1 to receive subcutaneous injections of adalimumab at either 160/80 mg at Week 0/2 and 40 mg every other week (eow) starting at Week 4 to Week 50, 80/40 mg at Week 0/2 and 40 mg eow starting at Week 4 to Week 50, or placebo eow starting at Week 0 to Week 50 under the double-blind condition. At or after Week 8, participants who have inadequate response during the double-blind period can switch to the rescue arm, where participants from the placebo group initially receive adalimumab 160 mg and 80 mg 2 weeks later and those from the adalimumab group receive adalimumab 40 mg initially and 2 weeks later under double-blind conditions. All participants in the rescue arm then receive 40 mg adalimumab eow until Week 50. Participants who complete the 52-week double-blind period receive open-label adalimumab 40 mg eow starting at Week 52 and continuing until the end of the study. Participants who have an inadequate response or disease flare can dose escalate to 80 mg eow at or after Week 60. Participants who dose escalate to 80 mg eow and continue to have an inadequate response or disease flare are withdrawn from the study.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

Keywords

  • Ulcerative Colitis
04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of ulcerative colitis for greater than 90 days prior to Baseline.
  • Active ulcerative colitis with a Mayo Score of 6-12 points at Baseline and endoscopy subscore of 2-3 during the Screening Period, despite concurrent treatment with at least one of the following (oral or or both as defined below):
  • Stable oral corticosteroid dose (prednisolone dose of ≥ 20 mg/day or equivalent) for at least 14 days prior to Baseline or stable oral corticosteroid dose (prednisolone of 5 to less than 20 mg/day) for at least 40 days prior to Baseline. And/or
  • At least a consecutive 90-day course of azathioprine or 6-mercaptopurine (6-MP) prior to Baseline, with a dose of azathioprine ≥ 50 mg/day or 6-MP ≥ 30 mg/day, or a dose that was the highest tolerated by the patient.

Exclusion criteria

Exclusion Criteria:

  • History of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Koch pouch, or ileostomy for ulcerative colitis or was planning bowel surgery.
  • Patients with disease limited to the rectum.
  • Indeterminate colitis and/or Crohn's disease.
  • Received any biological therapy (including infliximab) in the past.
  • History of tuberculosis or .
  • Pregnant women.
  • Patients with positive C. difficile stool assay at Screening.
  • Current diagnosis of fulminant colitis and/or toxic megacolon.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
274 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo subcutaneous injections every 2 weeks for 52 weeks. From Week 8, participants with an inadequate response could switch to rescue therapy, where they initially received adalimumab 160 mg, 80 mg 2 weeks later, and then 40 mg every other week. Participants who completed the 52-week double-blind period received open-label adalimumab 40 mg every other week, with the possibility to escalate to 80 mg every other week, until drug approval.

    Biological: adalimumab · Drug: placebo

  • Experimental
    Adalimumab 80 mg/40 mg

    Participants received adalimumab 80 mg on Day 1, 40 mg at Week 2 and 40 mg every other week from Week 4 to Week 50, via subcutaneous injection. From Week 8, participants with an inadequate response could switch to rescue therapy, where they received adalimumab 40 mg every other week. Participants who completed the 52-week double-blind period received open-label adalimumab 40 mg every other week, with the possibility to escalate to 80 mg every other week, until drug approval.

    Biological: adalimumab

  • Experimental
    Adalimumab 160 mg/80 mg

    Participants received adalimumab 160 mg on Day 1, 80 mg at Week 2 and 40 mg every other week from Week 4 to Week 50, via subcutaneous injection. From Week 8, participants with an inadequate response could switch to rescue therapy, where they received adalimumab 40 mg every other week. Participants who completed the 52-week double-blind period received open-label adalimumab 40 mg every other week, with the possibility to escalate to 80 mg every other week, until drug approval.

    Biological: adalimumab

Interventions

  • Biologicaladalimumab

    Also known as: ABT-D2E7 Humira

  • Drugplacebo
06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Clinical Remission at 8 Weeks

    Clinical remission was defined as a Mayo score ≤ 2 with no individual subscore \> 1. The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores: * Stool Frequency Subscore (SFS), based on the participant's diary and scored from zero (normal number of stools) to three (5 or more stools than normal); * Rectal Bleeding Subscore (RBS), based on the participant's diary and scored from zero (no blood) to three (blood only passed); * Endoscopy Subscore (ESS), based on colonoscopy or sigmoidoscopy and scored from zero (normal or inactive disease) to three (severe disease, spontaneous bleeding, ulceration); * Physician's Global Assessment (PGA) subscore, based on the physician's overall assessment, and scored from zero (normal) to three (severe disease). The total Mayo score ranges from 0 to 12 points, with higher scores representing more severe disease.

    Time frame: Week 8

  2. Percentage of Participants With Clinical Remission at 52 Weeks

    Clinical remission was defined as a Mayo score ≤ 2 with no individual subscore \> 1. The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores: * Stool Frequency Subscore (SFS), based on the participant's diary and scored from zero (normal number of stools) to three (5 or more stools than normal); * Rectal Bleeding Subscore (RBS), based on the participant's diary and scored from zero (no blood) to three (blood only passed); * Endoscopy Subscore (ESS), based on colonoscopy or sigmoidoscopy and scored from zero (normal or inactive disease) to three (severe disease, spontaneous bleeding, ulceration); * Physician's Global Assessment (PGA) subscore, based on the physician's overall assessment, and scored from zero (normal) to three (severe disease). The total Mayo score ranges from 0 to 12 points, with higher scores representing more severe disease.

    Time frame: Week 52

Secondary outcomes

  1. Percentage of Participants With Clinical Remission at 8, 32, and 52 Weeks

    Clinical remission was defined as a Mayo score ≤ 2 with no individual subscore \> 1. The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores: * Stool Frequency Subscore (SFS), based on the participant's diary and scored from zero (normal number of stools) to three (5 or more stools than normal); * Rectal Bleeding Subscore (RBS), based on the participant's diary and scored from zero (no blood) to three (blood only passed); * Endoscopy Subscore (ESS), based on colonoscopy or sigmoidoscopy and scores from zero (normal or inactive disease) to three (severe disease, spontaneous bleeding, ulceration); * Physician's Global Assessment (PGA) subscore, based on the physician's overall assessment, and scored from zero (normal) to three (severe disease). The total Mayo score ranges from 0 to 12 points, with higher scores representing more severe disease.

    Time frame: Weeks 8, 32, and 52

  2. Percentage of Participants With a Clinical Response

    A clinical response was defined as a decrease in Mayo score of ≥ 3 points and ≥ 30% from Baseline PLUS a decrease in the Rectal Bleeding Subscore (RBS) ≥ 1 or an absolute RBS of 0 or 1. The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores: * Stool Frequency Subscore, based on the participant's diary and scored from zero (normal number of stools) to three (5 or more stools than normal); * Rectal Bleeding Subscore, based on the participant's diary and scored from zero (no blood) to three (blood only passed); * Endoscopy Subscore, based on colonoscopy or sigmoidoscopy and scored from zero (normal or inactive disease) to three (severe disease, spontaneous bleeding, ulceration); * Physician's Global Assessment subscore, based on the physician's overall assessment, and scored from zero (normal) to three (severe disease). The total Mayo score ranges from 0 to 12 points, with higher scores representing more severe disease.

    Time frame: Baseline and Weeks 8, 32, and 52

  3. Percentage of Participants With Mucosal Healing

    Mucosal healing was defined as an endoscopy subscore of ≤ 1 and was assessed using flexible sigmoidoscopy performed at Weeks 8, 32, and 52. The endoscopy subscore ranges from zero to three as follows: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions), 3 = Severe disease (spontaneous bleeding, ulceration).

    Time frame: Weeks 8, 32, and 52

  4. Percentage of Participants With Rectal Bleeding Subscore Indicative of Mild Disease (≤ 1)

    Rectal bleeding was assessed from the participant's diary, taking the worst score from the 3 days prior to each study visit. The rectal bleeding subscore ranges from zero to three, according to the following scale: 0 = no blood seen, 1 = streaks of blood with stool less than half the time, 2 = obvious blood with stool most of the time, 3 = blood alone passed.

    Time frame: Weeks 8, 32, and 52

  5. Percentage of Participants With Physician's Global Assessment Subscore Indicative of Mild Disease (≤ 1)

    The Physician's Global Assessment Subscore acknowledges the three other subscores (Stool Frequency, Rectal Bleeding, and Endoscopy), the participant's daily record of abdominal discomfort and functional assessment, and other observations such as physical findings and the participant's performance status. Possible scores range from zero to three as follows: 0 = Normal (other subscores are 0), 1 = Mild disease (other subscores are mostly 1), 2 = Moderate disease (other subscores are 1 to 2), 3 = Severe disease (other subscores are 2 to 3).

    Time frame: Weeks 8, 32, and 52

  6. Percentage of Participants With Stool Frequency Subscore Indicative of Mild Disease (≤ 1)

    Stool frequency was assessed from the participant's diary, taking the worst score from the 3 days prior to each study visit. The stool frequency subscore ranges from zero to three, according to the following scale: 0 = Normal number of stools for this participant, 1 = 1-2 stools more than normal, 2 = 3-4 stools more than normal, 3 = 5 or more stools more than normal.

    Time frame: Weeks 8, 32, and 52

  7. Percentage of Inflammatory Bowel Disease Questionnaire (IBDQ) Responders

    An inflammatory bowel disease questionnaire responder was defined as a participant with at least a 16-point increase from Baseline in total Inflammatory Bowel Disease Questionnaire (IBDQ) score. The IBDQ is a 32-item questionnaire consisting of 4 dimensions: bowel-related symptoms, systemic function, social function, and emotional status. The responses to each question within each domain range from 1 (significant impairment) to 7 (no impairment), with the total score ranging from 32 (very poor) to 224 (perfect health-related quality of life).

    Time frame: Baseline and Weeks 8, 32, and 52

  8. Number of Participants With Adverse Events up to Week 8

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. For more details on adverse events please see the Adverse Event section below.

    Time frame: 8 weeks

  9. Number of Participants With Adverse Events up to Week 52

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. For more details on adverse events please see the Adverse Event section below.

    Time frame: 52 weeks

  10. Number of Participants With Adverse Events During the Adalimumab Treatment Period

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. For more details on adverse events please see the Adverse Event section below.

    Time frame: 221 weeks

07

Results

Posted Nov 27, 2012

Participant flow

Double-blind Period
Participant flow — Double-blind Period
MilestoneDouble-blind PlaceboDouble-blind Adalimumab 80 mg/40 mgDouble-blind Adalimumab 160 mg/80 mgAll Adalimumab
Started9687910
Treated9687900
Completed week 89285860
Completed7358600
Not completed2329310
Withdrew: Adverse event79130
Withdrew: Withdrawal by subject2300
Withdrew: Lack of efficacy1417160
Withdrew: Other0010
Withdrew: Mistreated with rescue study drug0010
Double-blind + Open-label Periods
Participant flow — Double-blind + Open-label Periods
MilestoneDouble-blind PlaceboDouble-blind Adalimumab 80 mg/40 mgDouble-blind Adalimumab 160 mg/80 mgAll Adalimumab
Started000266
Completed000119
Not completed000147
Withdrew: Lack of efficacy00074
Withdrew: Adverse event00047
Withdrew: Withdrawal by subject00020
Withdrew: Other0006

Outcome measures

PrimaryPercentage of Participants With Clinical Remission at 8 Weeks

Clinical remission was defined as a Mayo score ≤ 2 with no individual subscore \> 1. The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores: * Stool Frequency Subscore (SFS), based on the participant's diary and scored from zero (normal number of stools) to three (5 or more stools than normal); * Rectal Bleeding Subscore (RBS), based on the participant's diary and scored from zero (no blood) to three (blood only passed); * Endoscopy Subscore (ESS), based on colonoscopy or sigmoidoscopy and scored from zero (normal or inactive disease) to three (severe disease, spontaneous bleeding, ulceration); * Physician's Global Assessment (PGA) subscore, based on the physician's overall assessment, and scored from zero (normal) to three (severe disease). The total Mayo score ranges from 0 to 12 points, with higher scores representing more severe disease.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Remission at 8 Weeks
percentage of participantsPlaceboAdalimumab 80 mg/40 mgAdalimumab 160 mg/80 mg
Percentage of Participants With Clinical Remission at 8 Weeks11.513.810.0
PrimaryPercentage of Participants With Clinical Remission at 52 Weeks

Clinical remission was defined as a Mayo score ≤ 2 with no individual subscore \> 1. The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores: * Stool Frequency Subscore (SFS), based on the participant's diary and scored from zero (normal number of stools) to three (5 or more stools than normal); * Rectal Bleeding Subscore (RBS), based on the participant's diary and scored from zero (no blood) to three (blood only passed); * Endoscopy Subscore (ESS), based on colonoscopy or sigmoidoscopy and scored from zero (normal or inactive disease) to three (severe disease, spontaneous bleeding, ulceration); * Physician's Global Assessment (PGA) subscore, based on the physician's overall assessment, and scored from zero (normal) to three (severe disease). The total Mayo score ranges from 0 to 12 points, with higher scores representing more severe disease.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Remission at 52 Weeks
percentage of participantsPlaceboAdalimumab 80 mg/40 mgAdalimumab 160 mg/80 mg
Percentage of Participants With Clinical Remission at 52 Weeks7.326.420.0
SecondaryPercentage of Participants With Clinical Remission at 8, 32, and 52 Weeks

Clinical remission was defined as a Mayo score ≤ 2 with no individual subscore \> 1. The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores: * Stool Frequency Subscore (SFS), based on the participant's diary and scored from zero (normal number of stools) to three (5 or more stools than normal); * Rectal Bleeding Subscore (RBS), based on the participant's diary and scored from zero (no blood) to three (blood only passed); * Endoscopy Subscore (ESS), based on colonoscopy or sigmoidoscopy and scores from zero (normal or inactive disease) to three (severe disease, spontaneous bleeding, ulceration); * Physician's Global Assessment (PGA) subscore, based on the physician's overall assessment, and scored from zero (normal) to three (severe disease). The total Mayo score ranges from 0 to 12 points, with higher scores representing more severe disease.

Time frame:
Weeks 8, 32, and 52
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Remission at 8, 32, and 52 Weeks
percentage of participantsPlaceboAdalimumab 80 mg/40 mgAdalimumab 160 mg/80 mg
Week 811.513.810.0
Week 328.317.217.8
Week 527.326.420.0
SecondaryPercentage of Participants With a Clinical Response

A clinical response was defined as a decrease in Mayo score of ≥ 3 points and ≥ 30% from Baseline PLUS a decrease in the Rectal Bleeding Subscore (RBS) ≥ 1 or an absolute RBS of 0 or 1. The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores: * Stool Frequency Subscore, based on the participant's diary and scored from zero (normal number of stools) to three (5 or more stools than normal); * Rectal Bleeding Subscore, based on the participant's diary and scored from zero (no blood) to three (blood only passed); * Endoscopy Subscore, based on colonoscopy or sigmoidoscopy and scored from zero (normal or inactive disease) to three (severe disease, spontaneous bleeding, ulceration); * Physician's Global Assessment subscore, based on the physician's overall assessment, and scored from zero (normal) to three (severe disease). The total Mayo score ranges from 0 to 12 points, with higher scores representing more severe disease.

Time frame:
Baseline and Weeks 8, 32, and 52
Reported as:
Number · percentage of participants
Percentage of Participants With a Clinical Response
percentage of participantsPlaceboAdalimumab 80 mg/40 mgAdalimumab 160 mg/80 mg
Week 835.442.550.0
Week 3220.833.337.8
Week 5217.729.931.1
SecondaryPercentage of Participants With Mucosal Healing

Mucosal healing was defined as an endoscopy subscore of ≤ 1 and was assessed using flexible sigmoidoscopy performed at Weeks 8, 32, and 52. The endoscopy subscore ranges from zero to three as follows: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions), 3 = Severe disease (spontaneous bleeding, ulceration).

Time frame:
Weeks 8, 32, and 52
Reported as:
Number · percentage of participants
Percentage of Participants With Mucosal Healing
percentage of participantsPlaceboAdalimumab 80 mg/40 mgAdalimumab 160 mg/80 mg
Week 830.239.144.4
Week 3221.927.631.1
Week 5215.628.728.9
SecondaryPercentage of Participants With Rectal Bleeding Subscore Indicative of Mild Disease (≤ 1)

Rectal bleeding was assessed from the participant's diary, taking the worst score from the 3 days prior to each study visit. The rectal bleeding subscore ranges from zero to three, according to the following scale: 0 = no blood seen, 1 = streaks of blood with stool less than half the time, 2 = obvious blood with stool most of the time, 3 = blood alone passed.

Time frame:
Weeks 8, 32, and 52
Reported as:
Number · percentage of participants
Percentage of Participants With Rectal Bleeding Subscore Indicative of Mild Disease (≤ 1)
percentage of participantsPlaceboAdalimumab 80 mg/40 mgAdalimumab 160 mg/80 mg
Week 867.780.571.1
Week 3228.140.243.3
Week 5222.932.234.4
SecondaryPercentage of Participants With Physician's Global Assessment Subscore Indicative of Mild Disease (≤ 1)

The Physician's Global Assessment Subscore acknowledges the three other subscores (Stool Frequency, Rectal Bleeding, and Endoscopy), the participant's daily record of abdominal discomfort and functional assessment, and other observations such as physical findings and the participant's performance status. Possible scores range from zero to three as follows: 0 = Normal (other subscores are 0), 1 = Mild disease (other subscores are mostly 1), 2 = Moderate disease (other subscores are 1 to 2), 3 = Severe disease (other subscores are 2 to 3).

Time frame:
Weeks 8, 32, and 52
Reported as:
Number · percentage of participants
Percentage of Participants With Physician's Global Assessment Subscore Indicative of Mild Disease (≤ 1)
percentage of participantsPlaceboAdalimumab 80 mg/40 mgAdalimumab 160 mg/80 mg
Week 844.847.161.1
Week 3228.136.837.8
Week 5219.829.934.4
SecondaryPercentage of Participants With Stool Frequency Subscore Indicative of Mild Disease (≤ 1)

Stool frequency was assessed from the participant's diary, taking the worst score from the 3 days prior to each study visit. The stool frequency subscore ranges from zero to three, according to the following scale: 0 = Normal number of stools for this participant, 1 = 1-2 stools more than normal, 2 = 3-4 stools more than normal, 3 = 5 or more stools more than normal.

Time frame:
Weeks 8, 32, and 52
Reported as:
Number · percentage of participants
Percentage of Participants With Stool Frequency Subscore Indicative of Mild Disease (≤ 1)
percentage of participantsPlaceboAdalimumab 80 mg/40 mgAdalimumab 160 mg/80 mg
Week 832.334.540.0
Week 3220.833.331.1
Week 5213.528.728.9
SecondaryPercentage of Inflammatory Bowel Disease Questionnaire (IBDQ) Responders

An inflammatory bowel disease questionnaire responder was defined as a participant with at least a 16-point increase from Baseline in total Inflammatory Bowel Disease Questionnaire (IBDQ) score. The IBDQ is a 32-item questionnaire consisting of 4 dimensions: bowel-related symptoms, systemic function, social function, and emotional status. The responses to each question within each domain range from 1 (significant impairment) to 7 (no impairment), with the total score ranging from 32 (very poor) to 224 (perfect health-related quality of life).

Time frame:
Baseline and Weeks 8, 32, and 52
Reported as:
Number · percentage of participants
Percentage of Inflammatory Bowel Disease Questionnaire (IBDQ) Responders
percentage of participantsPlaceboAdalimumab 80 mg/40 mgAdalimumab 160 mg/80 mg
Week 839.648.342.2
Week 3221.933.328.9
Week 5212.529.921.1
SecondaryNumber of Participants With Adverse Events up to Week 8

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. For more details on adverse events please see the Adverse Event section below.

Time frame:
8 weeks
Reported as:
Number · participants
Number of Participants With Adverse Events up to Week 8
participantsPlaceboAdalimumab 80 mg/40 mgAdalimumab 160 mg/80 mg
Any adverse event454940
Any AE at least possibly drug related101412
Any serious adverse event724
Any AE leading to discontinuation of study drug406
SecondaryNumber of Participants With Adverse Events up to Week 52

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. For more details on adverse events please see the Adverse Event section below.

Time frame:
52 weeks
Reported as:
Number · participants
Number of Participants With Adverse Events up to Week 52
participantsPlaceboAdalimumab 80 mg/40 mgAdalimumab 160 mg/80 mg
Any adverse event676875
Any AE at least possibly drug related172332
Any serious adverse event121410
Any AE leading to discontinuation of study drug5512
SecondaryNumber of Participants With Adverse Events During the Adalimumab Treatment Period

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. For more details on adverse events please see the Adverse Event section below.

Time frame:
221 weeks
Reported as:
Number · participants
Number of Participants With Adverse Events During the Adalimumab Treatment Period
participantsAll Adalimumab
Any adverse event261
Any AE at least possibly drug related142
Any serious adverse event90
Any AE leading to discontinuation of study drug37

Adverse events

Collected over For the 3 randomized treatment arms, adverse events (AEs) were reported from the time of study drug administration up to Week 52 (double-blind period); for All Adalimumab, AEs were reported up to 221 weeks+70 days following discontinuation of study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-blind Placebo—13/96 (13.5%)51/96 (53.1%)
Double-blind Adalimumab 80 mg/40 mg—14/87 (16.1%)47/87 (54%)
Double-blind Adalimumab 160 mg/80 mg—10/90 (11.1%)60/90 (66.7%)
All Adalimumab—90/266 (33.8%)235/266 (88.3%)
Most frequent serious events
Showing 10 of 73
Most frequent serious events
EventDouble-blind PlaceboDouble-blind Adalimumab 80 mg/40 mgDouble-blind Adalimumab 160 mg/80 mgAll Adalimumab
COLITIS ULCERATIVEGastrointestinal disorders8/965/875/9038/266
COLONIC POLYPGastrointestinal disorders0/961/870/903/266
ADVERSE DRUG REACTIONGeneral disorders0/961/870/901/266
BRONCHITISInfections and infestations0/961/871/902/266
PNEUMONIA BACTERIALInfections and infestations0/961/871/903/266
PYELONEPHRITIS ACUTEInfections and infestations0/961/870/902/266
HAND FRACTUREInjury, poisoning and procedural complications0/961/870/901/266
WOUNDInjury, poisoning and procedural complications0/961/870/901/266
DRUG LEVELInvestigations0/961/870/901/266
ARTHRALGIAMusculoskeletal and connective tissue disorders0/961/870/901/266
Most frequent other events
Showing 10 of 25
Most frequent other events
EventDouble-blind PlaceboDouble-blind Adalimumab 80 mg/40 mgDouble-blind Adalimumab 160 mg/80 mgAll Adalimumab
NASOPHARYNGITISInfections and infestations21/9619/8730/90162/266
HEADACHENervous system disorders6/963/877/9042/266
BACK PAINMusculoskeletal and connective tissue disorders3/963/874/9031/266
DENTAL CARIESGastrointestinal disorders5/966/873/9027/266
UPPER RESPIRATORY TRACT INFLAMMATIONRespiratory, thoracic and mediastinal disorders4/963/875/9027/266
ECZEMASkin and subcutaneous tissue disorders2/964/871/9027/266
RASHSkin and subcutaneous tissue disorders5/964/873/9027/266
NAUSEAGastrointestinal disorders4/962/875/9026/266
INJECTION SITE REACTIONGeneral disorders2/967/876/9025/266
IRON DEFICIENCY ANAEMIABlood and lymphatic system disorders7/964/878/9024/266

Baseline characteristics

1 participant in the adalimumab 160 mg/80 mg arm was incorrectly treated with open-label (rescue) study drug at Week 0, and was not included in Baseline Characteristics.

Age, Continuous
Age, Continuous(years)PlaceboAdalimumab 80 mg/40 mgAdalimumab 160 mg/80 mgTotal
Mean41.3 ± 13.5644.4 ± 15.0442.5 ± 14.5642.7 ± 14.38
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAdalimumab 80 mg/40 mgAdalimumab 160 mg/80 mgTotal
Female26372992
Male705061181
Region of Enrollment
Region of Enrollment(participants)PlaceboAdalimumab 80 mg/40 mgAdalimumab 160 mg/80 mgTotal
Japan968790273
Mayo score
Mayo score(scores on a scale)PlaceboAdalimumab 80 mg/40 mgAdalimumab 160 mg/80 mgTotal
Mean8.5 ± 1.568.5 ± 1.428.6 ± 1.448.5 ± 1.47
08

Study locations

65 sites
  • Site Reference ID/Investigator# 47136
    Asahikawa, Japan
  • Site Reference ID/Investigator# 47159
    Chiba, Japan
  • Site Reference ID/Investigator# 47183
    Chikushino, Japan
  • Site Reference ID/Investigator# 47135
    Fukuoka-shi, Japan
  • Site Reference ID/Investigator# 47182
    Fukuoka-shi, Japan
  • Site Reference ID/Investigator# 47124
    Hamamatsu, Japan
  • Site Reference ID/Investigator# 47130
    Hirakata-shi, Japan
  • Site Reference ID/Investigator# 47103
    Hirosaki, Japan
  • Site Reference ID/Investigator# 47131
    Hiroshima-shi, Japan
  • Site Reference ID/Investigator# 47178
    Hiroshima, Japan
  • Site Reference ID/Investigator# 47179
    Hiroshima, Japan
  • Site Reference ID/Investigator# 47176
    Izumo, Japan
  • Site Reference ID/Investigator# 47226
    Kagoshima, Japan
  • Site Reference ID/Investigator# 47123
    Kanazawa-shi, Japan
  • Site Reference ID/Investigator# 47160
    Kashiwa, Japan
  • Site Reference ID/Investigator# 47108
    Kawagoe, Japan
  • Site Reference ID/Investigator# 47107
    Koshigaya, Japan
  • Site Reference ID/Investigator# 47181
    Kurume, Japan
  • Site Reference ID/Investigator# 47222
    Kurume, Japan
  • Site Reference ID/Investigator# 47223
    Kurume, Japan
  • Site Reference ID/Investigator# 47170
    Kyoto-shi, Japan
  • Site Reference ID/Investigator# 47171
    Kyoto-shi, Japan
  • Site Reference ID/Investigator# 47127
    Kyoto, Japan
  • Site Reference ID/Investigator# 47172
    Kyoto, Japan
  • Site Reference ID/Investigator# 47134
    Matsuyama-shi, Japan
  • Site Reference ID/Investigator# 47225
    Miyazaki, Japan
  • Site Reference ID/Investigator# 47138
    Morioka-shi, Japan
  • Site Reference ID/Investigator# 47168
    Nagakute-shi, Japan
  • Site Reference ID/Investigator# 47125
    Nagoya-shi, Japan
  • Site Reference ID/Investigator# 47126
    Nagoya-shi, Japan
  • Site Reference ID/Investigator# 47166
    Nagoya-shi, Japan
  • Site Reference ID/Investigator# 47122
    Niigata-shi, Japan
  • Site Reference ID/Investigator# 47227
    Nishihara, Japan
  • Site Reference ID/Investigator# 47174
    Nishinomiya-shi, Japan
  • Site Reference ID/Investigator# 47224
    Oita, Japan
  • Site Reference ID/Investigator# 47177
    Okayama-shi, Japan
  • Site Reference ID/Investigator# 47228
    Okinawa, Japan
  • Site Reference ID/Investigator# 47128
    Osaka-shi, Japan
  • Site Reference ID/Investigator# 47129
    Osaka, Japan
  • Site Reference ID/Investigator# 47169
    Otsu-shi, Japan
  • Site Reference ID/Investigator# 47118
    Sagamihara-shi, Japan
  • Site Reference ID/Investigator# 47158
    Saitama-shi, Japan
  • Site Reference ID/Investigator# 47109
    Sakura, Japan
  • Site Reference ID/Investigator# 15853
    Sapporo-shi, Japan
  • Site Reference ID/Investigator# 47137
    Sapporo, Japan
  • Site Reference ID/Investigator# 47104
    Sendai-shi, Japan
  • Site Reference ID/Investigator# 47147
    Sendai-shi, Japan
  • Site Reference ID/Investigator# 47180
    Susaki-shi, Japan
  • Site Reference ID/Investigator# 47133
    Takamatsu, Japan
  • Site Reference ID/Investigator# 47173
    Takatsuki-shi, Japan
  • Site Reference ID/Investigator# 47106
    Tokorozawa-shi, Japan
  • Site Reference ID/Investigator# 47132
    Tokushima, Japan
  • Site Reference ID/Investigator# 47110
    Tokyo, Japan
  • Site Reference ID/Investigator# 47111
    Tokyo, Japan
  • Site Reference ID/Investigator# 47112
    Tokyo, Japan
  • Site Reference ID/Investigator# 47116
    Tokyo, Japan
  • Site Reference ID/Investigator# 47117
    Tokyo, Japan
  • Site Reference ID/Investigator# 47161
    Tokyo, Japan
  • Site Reference ID/Investigator# 47164
    Tokyo, Japan
  • Site Reference ID/Investigator# 47165
    Toyama, Japan
  • Site Reference ID/Investigator# 47167
    Toyoake, Japan
  • Site Reference ID/Investigator# 47105
    Yamagata-shi, Japan
  • Site Reference ID/Investigator# 47175
    Yamatotakada, Japan
  • Site Reference ID/Investigator# 47121
    Yokohama-shi, Japan
  • Site Reference ID/Investigator# 47120
    Yokohama, Japan
09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of May 2011 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2012, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2009
First posted
Mar 2, 2009
Start
Feb 2009
Primary completionActual
May 2011
CompletionActual
Aug 2013
Results first posted
Nov 27, 2012
Last update
Sep 5, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00853099
Collaborators
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Mar 2, 2009
Start date
Feb 2009
Primary completion
May 2011
Completion
Aug 2013
Results posted
Nov 27, 2012
Last update
Sep 5, 2014

Study contacts

Morio Ozawa, MS
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion